Nabiximols
- Generic Name
- Nabiximols
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H60O4
- CAS Number
- 56575-23-6
- Unique Ingredient Identifier
- K4H93P747O
- Background
Nabiximols (tradename Sativex®) is a whole plant extract from the Cannabis species Cannabis sativa L. that has been purified into the active components CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol). For trademark purposes, purified CBD is branded as Nabidiolex®, while THC is purified as the product Tetrabinex®. Sativex® is available in a 1:1 formu...
- Indication
In Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy.
...
- Associated Conditions
- -
- Associated Therapies
- -
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 397
- Registration Number
- NCT01262651
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.